ARMGO Pharma
Tarrytown
About ARMGO Pharma
ARMGO Pharma, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat debilitating cardiac, skeletal muscular, and neurological disorders. It offers rycals, which are calcium release channel stabilizers that act on ryanodine receptor/calcium release channel, a therapeutic target located on the sarcoplasmic/endoplasmic reticulum of the cell for treating chronic heart failure, cardiac arrythmias, and muscle disorders, as well as cognitive disorders, malignant hyperthermia, diabetes, chronic obstructive pulmonary disease, high blood pressure, and bladder dysfunction. The company was incorporated in 2004 and is based in Tarrytown, New York with an additional office in New York, New York.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $36.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Dec 2021)
- Website: armgo.com
- Phone: 2129230316
Industries & Categories
Biotechnology, Developer Platform, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/armgo-pharma-114694 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.